Susquehanna International Group
ODT

Susquehanna International Group’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Susquehanna International Group’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,000
Closed -$96K – 13593
2021
Q1 		$96K Sell
28,000
-31,500
-53% -$595K ﹤0.01% 11883
2020
Q4 		$1.14M Buy
59,500
+34,100
+134% +$526K ﹤0.01% 6409
2020
Q3 		$341K Sell
25,400
-14,900
-37% -$422K ﹤0.01% 8454
2020
Q2 		$1.71M Sell
40,300
-18,300
-31% -$592K ﹤0.01% 4789
2020
Q1 		$1.62M Buy
+58,600
New +$1.71M ﹤0.01% 4364

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Susquehanna International Group's ODT Position: Q4 2021 in Review

Susquehanna International Group sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 35,475 shares — an estimated $103K sold.

Susquehanna International Group first reported a position in ODT in Q1 2020 and held it in 6 quarters. The position peaked at $1.08M in Q4 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • Susquehanna International Group reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Susquehanna International Group sold 35,475 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $103K.
  • Susquehanna International Group first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
  • Susquehanna International Group's Odonate Therapeutics, Inc. Common Stock position peaked at $1.08M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.